Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-Blind, Placebo-Controlled Randomized Clinical Trial
JAMA Dermatol 2021 Aug 18;[EPub Ahead of Print], S Glatt, GBE Jemec, S Forman, C Sayed, G Schmieder, J Weisman, R Rolleri, S Seegobin, D Baeten, L Ionescu, CC Zouboulis, S ShawFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.